title: Intermittent androgen deprivation for locally advanced prostate cancer. Preliminary experience from an ongoing randomized controlled study of the South European urooncological group.
authors.affiliation: Hospital do Desterro, Lisbon, Portugal. urologia@hdesterro.min-saude.pt
authors.forename: F
authors.initials: F
authors.lastname: Calais da Silva
authors.forename: A
authors.initials: A
authors.lastname: Bono
authors.forename: P
authors.initials: P
authors.lastname: Whelan
authors.forename: M
authors.initials: M
authors.lastname: Brausi
authors.forename: M
authors.initials: M
authors.lastname: Queimadelos
authors.forename: J
authors.initials: J
authors.lastname: Portillo
authors.forename: Z
authors.initials: Z
authors.lastname: Kirkali
authors.forename: C
authors.initials: C
authors.lastname: Robertson
mesh_terms: D000726:Androgen Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage* / Q000009:adverse effects; D017322:Clinical Trials, Phase II as Topic; D004334:Drug Administration Schedule; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D016896:Treatment Outcome
chemical_list: D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal